| 2.41 0.43 (21.72%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.06 |
1-year : | 3.57 |
| Resists | First : | 2.61 |
Second : | 3.06 |
| Pivot price | 1.98 |
|||
| Supports | First : | 2.03 |
Second : | 1.67 |
| MAs | MA(5) : | 1.99 |
MA(20) : | 2.07 |
| MA(100) : | 2.08  |
MA(250) : | 3.58 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55 |
D(3) : | 34.9 |
| RSI | RSI(14): 65.9 |
|||
| 52-week | High : | 7.8 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PEPG ] has closed above the upper band by 6.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.46 | 2.46 - 2.47 |
| Low: | 2.04 - 2.05 | 2.05 - 2.06 |
| Close: | 2.39 - 2.41 | 2.41 - 2.42 |
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Thu, 06 Aug 2026
PepGen Inc. 1H 2026: Net loss $(35.6M), EPS $(0.51) — 10-Q Summary - TradingView
Thu, 06 Aug 2026
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - Business Wire
Tue, 04 Aug 2026
Class Action Filed Against PepGen Inc. (PEPG) Over Securities Violations - Contact Levi & Korsinsky Today - The National Law Review
Sun, 02 Aug 2026
Shareholders of PepGen Should Contact Faruqi & Faruqi Before August 11, 2025 to Discuss Your Rights - PEPG - TMX Newsfile
Thu, 30 Jul 2026
PepGen Inc. Revenue Breakdown – NASDAQ:PEPG - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 88.3 (%) |
| Shares Short | 4,530 (K) |
| Shares Short P.Month | 3,850 (K) |
| EPS | -1.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.8 % |
| Return on Equity (ttm) | -68.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -1.66 |
| PEG Ratio | 0 |
| Price to Book value | 1.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|